Evicenter
Opdivo (nivolumab) in Metastatic non-small cell lung cancer
Manufacturer
Bristol-Myers Squibb Company
Prescribing information
Opdivo (opens in a new tab)
Questions
60
Last updated

All questions

Indication: Opdivo (nivolumab) in metastatic non-small cell lung cancer

5 questions · 5 sources

Indication

What is Opdivo approved for in metastatic non-small cell lung cancer?

What is Opdivo Qvantig approved for in metastatic NSCLC?

Applies to Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

Can Opdivo Qvantig be given with Yervoy for lung cancer?

Applies to Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

Testing

Does Opdivo plus Yervoy require PD-L1 testing in metastatic NSCLC?

Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

Note: The quoted PD-L1 selection statement applies to first-line Opdivo with Yervoy.

Eligibility

Can Opdivo be used for lung cancer with EGFR or ALK mutations?